The role of LOX as a prostate cancer biomarker is complex, since one study found that high LOX expression in the non-malignant prostate epithelium predicts a poor outcome in prostate cancer patients that are managed by watchful waiting. The gene discussed is LOX; the disease is prostate carcinoma.